SCHEMBL4800518

SCHEMBL4800518

COC(=O)c1ccc(OCCCON=C(Cc2ccccc2)c2c[nH]c3ccccc23)cc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.46
CREBBP Q92793 1/20 0.46
MAPT P10636 3/20 0.40
POLB P06746 1/20 0.40
GABRP O00591 3/20 0.40
GABRD O14764 3/20 0.40
GABRA1 P14867 3/20 0.40
GABRB1 P18505 3/20 0.40
GABRG2 P18507 3/20 0.40
GABRB3 P28472 3/20 0.40
GABRA5 P31644 3/20 0.40
GABRA3 P34903 3/20 0.40
GABRA2 P47869 3/20 0.40
GABRB2 P47870 3/20 0.40
GABRA4 P48169 3/20 0.40
GABRE P78334 3/20 0.40
GABRA6 Q16445 3/20 0.40
GABRG1 Q8N1C3 3/20 0.40
GABRG3 Q99928 3/20 0.40
GABRQ Q9UN88 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900907 0.76 PTGS1 (0.54) NR4A2CREBBPMAPTPOLBMEN1
SCHEMBL11461356 0.73 PPARD (0.59) MAPTPOLBNPC1RAB9AMAOB
SCHEMBL7909139 0.72 MAOB (0.56) MEN1KMT2AMAOB
SCHEMBL7911142 0.72 MTNR1A (0.53) MAPTPOLBMEN1KMT2AMTNR1A
SCHEMBL7901014 0.71 MAOB (0.57) MAPTPOLBMEN1KMT2AMAOB
SCHEMBL629952 0.70 MAOB (0.74) NPC1RAB9ASMN1; SMN2MAOB
SCHEMBL9023222 0.70 NR4A2 (0.66) NR4A2CREBBPMAPTPOLBMEN1
SCHEMBL2433763 0.70 MDH2 (0.69) NR4A2CREBBPMEN1KMT2ANPC1
SCHEMBL29032428 0.69 MAOB (0.58) MAPTPOLBRAB9AMAOB
SCHEMBL21662494 0.69 CA12 (0.58) MAPTPOLBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342039-B2 Substituted indole oximes WYETH (US) 2008-03-11 US disclosed
EP-1667670-A1 4-(1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-14 EP disclosed
US-20050119326-A1 Substituted aryloximes WYETH (US) 2005-06-02 US disclosed
WO-2005030192-A1 4- (1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY) -BENZIOC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS WYETH (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119326-A1 Substituted aryloximes IDO2, TDO2, IDO1 NR4A2 1335/4885CREBBP 1589/4885MAPT 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.